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We analysed the effects of small interfering RNA (siRNA)-mediated silencing of Apollon, a member of the inhibitors of apoptosis
protein family, on the proliferative potential and ability of human breast cancer cell lines to undergo apoptosis. In wild-type p53
ZR75.1 cells, Apollon knockdown resulted in a marked, time-dependent decline of cell growth and an increased rate of apoptosis,
which was associated with p53 stabilisation and activation of the mitochondrial-dependent apoptotic pathway. Pre-incubation of cells
with a p53-specific siRNA resulted in a partial rescue of cell growth inhibition, as well as in a marked reduction of the apoptotic
response, indicating p53 as a major player in cell growth impairment consequent on Apollon silencing. Apollon knockdown induced
consistently less pronounced anti-proliferative and pro-apoptotic effects in mutant p53 MDA-MB-231 cells than in ZR75.1 cells.
Furthermore, the activation of caspase-3 seemed to be essential for the induction of apoptosis after Apollon knockdown, as the
Apollon-specific siRNA had no effect on the viability of caspase-3-deficient, wild-type p53 MCF-7 cells or the ZR75.1 cells after RNA
interference-mediated caspase-3 silencing. Our results indicate that p53 stabilisation and caspase-3 activation concur to determine
the apoptotic response mediated by Apollon knockdown in breast cancer cells, and suggest Apollon to be a potential new
therapeutic target for this malignancy.
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Apoptosis is a tightly regulated process, which plays a central role
in the development and homeostasis of multicellular organisms. Its
deregulation is involved in a wide spectrum of diseases including
cancer, in which an overexpression of anti-apoptotic proteins
endows cells with a selective survival advantage that promotes
malignancy (Green and Evan, 2002). The members of the
inhibitors of apoptosis protein (IAP) family have been proved to
be crucial negative regulators of apoptosis (Srinivasula and
Ashwell, 2008), and some of these proteins were found to be
expressed highly in human tumours (Hong et al, 2003; Yang et al,
2003; Srinivasula and Ashwell, 2008).
Apollon, also known as Bruce or BIRC6, is the largest member of
the IAP family, containing one baculoviral IAP repeat domain at
its N-terminal region and a C-terminal E2 motif, which can form
thioester bonds with ubiquitin (Chen et al, 1999). It has also been
suggested to function as an E3 ligase, and is itself regulated by
ubiquitin-dependent degradation mediated by E2 UbcH5 and E3
Nrdp1 (Qiu and Goldberg, 2005). Although the physiological role
of Apollon in counteracting apoptosis is largely unknown, the
available information indicates that Apollon exerts its cytoprotec-
tive activity by promoting ubiquitination and degradation of the
pro-apoptotic protein Smac/DIABLO and by inhibiting caspase
activity (Hao et al, 2004; Qiu and Goldberg, 2005). It has been
reported that Apollon is upregulated in some brain tumour cell
lines that are resistant to certain DNA-damaging agents
(Chen et al, 1999), and also that its overexpression is associated
with poor prognosis in childhood acute myeloid leukaemia
(Sung et al, 2007). These findings, together with preliminary
evidence concerning the possibility of sensitising tumour cells to
apoptosis induced by some anticancer drugs through antisense
oligonucleotide- or small interfering RNA (siRNA)-mediated
downregulation of Apollon (Chen et al, 1999; Qiu et al, 2004;
Chu et al, 2008), has led researchers to consider the gene as a
possible new therapeutic target.
With the aim to elucidate the molecular bases responsible for
the cytoprotective activity of Apollon in breast cancer, we
investigated the effects of its knockdown, accomplished through
RNA interference (RNAi), on the proliferative potential and its
ability to undergo apoptosis of established cell lines differing in the
TP53 gene status. The results of this study indicate that wild-type
p53 stabilisation and caspase-3 activation concur in determining
the apoptotic response, consequent on Apollon knockdown in
breast cancer cells.
MATERIALS AND METHODS
Cell lines
We used three human breast carcinoma cell lines: ZR75.1 and
the caspase-3-deficient MCF-7 cell lines expressing wild-type
p53, and the MDA-MB-231 cell line expressing a mutant p53
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s(Sheikh et al, 1993; Janicke et al, 1998; Yang et al, 1998; Gartel et al,
2003) (American Type Culture Collection, Rockville, MD, USA).
The ZR75.1 and MCF-7 cells were grown in the RPMI-1640
medium (Lonza Milano s.r.l, Treviglio, Italy) supplemented with
10% foetal bovine serum; the MDA-MB-231 cells were cultured
using the D-MEM/F12 medium (Lonza Milano s.r.l) supplemented
with 5% foetal bovine serum. Cells were maintained as a
monolayer in a humidified incubator at 371C with a supply of
5% CO2:95% air atmosphere.
Design and synthesis of small interfering RNAs
Four different siRNAs targeting specific consensus sequences
(50-AA(N19)-30), within the open reading frame of Apollon mRNA
(GeneBank accession no. NM_016252), were designed using a
siRNA target finder tool (http://www.ambion.com) (Table 1). A
BLAST search (http://www.ncbi.nlm.nih.gov/BLAST) for selected
siRNA sequences was carried out to exclude any alignment with
other sequences in the human genome. A control siRNA made up
of a scrambled sequence with no significant homology to any
known human mRNA was included in this study (Table 1). Small
interfering RNAs were manufactured by the Eurofins MWG
Operon (Ebersberg, Germany) as preformed and purified duplexes.
Transfection procedures
The day before transfection, breast cancer cells were seeded at a
density of 2 10
5 per 25-cm
2 flask. A given amount of each
Apollon and control siRNA was mixed with Lipofectamine2000t
(Invitrogen, San Giuliano Milanese, Italy) for 20min at room
temperature. The mixtures were then applied to the cells in a
volume of Opti-MEM I (Invitrogen), giving a final concentration of
10nM for each siRNA. After a 4-h incubation at 371C, cells were
washed with PBS and a culture medium supplemented with serum
was added. At different intervals after transfection (from 24 to
96h), cells were collected by trypsinisation and used subsequently
in the different assays. In cotransfection experiments, cells were
treated with 25nM caspase-3-specific siRNA or p53-specific siRNA
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), cultured for
24h at 371C, and then transfected with 10nM Apollon or control
siRNA as described earlier. Cells exposed to Lipofectamine2000
alone were referred to as mock control throughout this study.
Protein extraction and western blot analysis
Western blots were carried out for the following proteins:
apoptosis inducing factor (AIF), Apollon, Bad, Bax, cIAP1, cIAP2,
cytochrome c, p53, Smac/DIABLO, survivin and XIAP.
Cells were lysed, and mitochondrial and cytosolic fractions
were obtained using a mitochondrial/cytosol fractionation
kit (Medical & Biological Laboratories, Naka-ku Nagoya, Japan).
Samples containing 40mg of protein per lane were separated on
precast 3–8% NuPAGEt tris-acetate (for the detection of Apollon)
or 12% NuPAGE bis-tris (for the detection of AIF, Bad, Bax, cIAP1,
cIAP2, cytochrome c, p53, Smac/DIABLO, survivin and XIAP) gels
(Invitrogen), and were transferred onto Hybond ECL nitrocellulose
membranes (GE Healthcare Europe GmbH, Cologno Monzese,
Italy) using the NuPAGE transfer buffer (Invitrogen). Nitrocellu-
lose membranes were blocked in PBS-Tween 20 with 5% skim
milk, first incubated with the primary antibodies (Abcam Inc.,
Cambridge, MA, USA) and then with the secondary peroxidase-
linked whole antibodies (GE Healthcare Europe). Bound anti-
bodies were detected using the SuperSignal
s West PICO
chemiluminescent substrate (Pierce Biotechnology Inc., Rockford,
IL, USA). b-Actin and COX IV monoclonal antibodies (Abcam)
were used to confirm equal protein loading on the gel, and also to
show the relative purity of the cytosolic or mitochondrial fractions.
Filters were autoradiographed, and autoradiographs were scanned
and quantified by densitometric analysis.
Cell growth inhibition assay and apoptosis analysis
At different intervals after transfection with siRNAs, adherent cells
were trypsinised and counted in a particle counter (Coulter
Counter, Coulter Electronics, Luton, UK). The cell viability was
determined by the Trypan blue dye exclusion test. Each experi-
mental sample was run in triplicate.
For apoptosis analysis, adherent cells were pooled together with
detached cells and then scored for nuclear morphology of apoptosis
(chromatin condensation and DNA fragmentation) by labelling
with a solution containing 50mgml
 1 of propidium iodide,
50mgml
 1 of RNase and 0.05% Nonidet P40 in PBS. After staining,
the slides were examined using fluorescence microscopy, and the
percentage of cells with an apoptotic nuclear morphology was
determined by scoring at least 500 cells in each sample. In the same
cellular samples, the catalytic activity of caspase-9, caspase-3 and
caspase-8 was measured as the ability to cleave the specific
substrates N-acetyl-Leu-Glu-His-Asp-AMC (LEHD-AMC), N-acetyl-
Asp-Glu-Val-Asp-AMC (DEVD-AMC) and N-acetyl-Ile-Glu-Thr-
Asp-AMC (IETD-AMC) by means of the APOPCYTO/caspase-9,
APOPCYTO/caspase-3 and APOPCYTO/caspase-8 assay kits
(Medical & Biological Laboratories), respectively. The hydrolysis
of the specific substrates for the different caspases was monitored
by spectrofluorometry with 380-nm excitation and 460-nm
emission filters.
Quantification of cytochrome c release
The cytochrome c release was measured using the Cytochrome c
ELISA kit (Medical & Biological Laboratories). After colour
development had stopped, the absorbance at 450nm was measured
on the microplate reader. Percent release of cytochrome c was
calculated as the amount of cytosolic cytochrome c divided by the
total amount of cytosolic and mitochondrial cytochrome c.
Total RNA isolation and RT–PCR
Total RNA isolated using Qiagen RNeasy Mini Kit (Qiagen, Milan,
Italy) was reverse-transcribed in the presence of random hexamers
using the GeneAmp RNA Core Kit (Applied Biosystems, Foster
City, CA, USA). To assess the p53 mRNA expression, the resultant
cDNA was amplified through optimised PCR cycling conditions in
the presence of specific primer pair (Maxwell et al, 1999): the sense
primer was 50-TCTTTGCATTCTGGGACAGCC-30 and the anti-
sense primer was 50-AGCTCGTGGTGAGGCTCCCCT-30 (Eurofins
MWG Operon). A fragment corresponding to b-actin was used as
the standard of the amplification reaction. The PCR products were
verified by gel electrophoresis, and the images were acquired by a
ScanJET IIcx/T scanner (Hewlett Packard, Milano, Italy).
Table 1 Sequences of control siRNA and siRNAs targeting Apollon
mRNA
Name Sequence
Ctr CAAUCUGUAGAUAUAGUGAdTdT
dTdTGUUAGACAUCUAUAUCACU
Apo1 AGAAAUUGACCUUGAGUUAdTdT
dTdTUCUUUAACUGGAACUCAAU
Apo2 GCAGUACAUGGUAUGAUUAdTdT
dTdTCGUCAUGUACCAUACUAAU
Apo3 AGACUGCUGAGAUAGUUUAdTdT
dTdTUCUGACGACUCUAUCAAAU
Apo4 UGAAUCCUGCACUAAUUCAdTdT
dTdTACUUAGGACGUGAUUAAGU
siRNA¼small interfering RNA
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Student’s t-test was used to analyse the differences between control
and siRNA-transfected cells in terms of protein expression, cell
growth, rate of apoptosis, in vitro catalytic activity of caspase-9,
caspase-3 and caspase-8, and release of cytochrome c. P-values
o0.05 (two-sided) were considered statistically significant.
RESULTS
siRNA-mediated Apollon knockdown affects cell growth in
breast cancer cells
To gain insight into the role of Apollon in breast cancer cell
survival, we used an RNAi-based strategy to downregulate its
expression in three human breast cancer cell lines, characterised
by a different TP53 gene status: ZR75.1 and MCF-7 cells bearing
wild-type p53 and MDA-MB-231 cells carrying mutant p53. We
first tested the effectiveness of four 21-mer siRNAs targeting
different portions within the Apollon mRNA (Table 1), to silence
the Apollon gene expression in the ZR75.1 cell line. Western
blotting experiments carried out in cells collected at different
intervals (24–72h), after a 4-h transfection with 10nM of each
Apollon-specific siRNA, showed a variable degree of protein
expression inhibition as a function of the different oligomer used
(Figure 1A and B). Specifically, the abundance of Apollon protein
was reduced significantly starting from 24h after transfection with
every siRNA as compared with that in mock control (Figure 1A
and B). The extent of the inhibition increased over time and
reached its maximum at 72h after transfection with all siRNAs
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Figure 1 Downregulation of Apollon by siRNA in breast cancer cells. (A) A representative western blot experiment showing Apollon protein expression
levels in ZR75.1 cells exposed to Lipofectamine2000t alone (mock control, M) or transfected with 10nM control (ctr) and Apollon (1–4) siRNAs at various
time points after transfection. (B) Quantification of the Apollon protein expression in ZR75.1 cells. Data are reported as the percentage of the Apollon
expression in cells transfected with control or Apollon-specific siRNAs compared with mock control and represent the mean values±s.d. of at least three
independent experiments. *Po0.01 and **Po0.001 vs mock control. (C) A representative western blot experiment showing Apollon protein expression
levels in MDA-MB-231 and MCF-7 cells exposed to mock control (M) or transfected with ctr and Apo2 siRNAs at various time points after transfection. (D)
Quantification of the Apollon protein expression in MDA-MB-231 and MCF-7 cells. Data are reported as the percentage of Apollon expression in cells
transfected with ctr (empty column) or Apo2 (grey column) siRNAs compared with mock control and represent the mean values±s.d. of at least three
independent experiments. *Po0.01 and **Po0.001 vs mock control. (E) A representative western blot experiment showing the expression of other anti-
apoptotic proteins belonging to the IAP family in ZR75.1 cells 72h after transfection with ctr and Apo2 siRNAs. IAP¼inhibitors of apoptosis protein;
siRNA¼small interfering RNA.
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s(Figure 1A and B). Transfection with the Apollon-specific siRNA
(Apo2), which was able to induce the greatest inhibition of Apollon
expression in the ZR75.1 cell line, also resulted in a significant and
time-dependent decline of the protein in the MDA-MB-231 and
MCF-7 cell lines (Figure 1C and D). Conversely, Apo2 did not
modify the expression of other anti-apoptotic proteins belonging
to the IAP family, including cIAP1, cIAP2, XIAP and survivin
(Figure 1E).
The effects of Apollon downregulation on the in vitro
proliferative potential of breast cancer cells were further
evaluated using Apo2, which was able to inhibit the protein
expression by B90% at 72h after transfection in all cell lines
(Figure 1B and D). In ZR75.1 cells, inhibition of Apollon
resulted in a significant and time-dependent decrease in viable
cell number as compared with that in mock control (Figure 2,
upper panel). Such a growth inhibition was appreciable starting
48h after transfection and increasing progressively over time.
Although to a lesser extent, cell growth was affected by Apollon
knockdown also in the MDA-MB-231 cells, and a significant
reduction in cell number compared with that in mock control
was appreciable at 72 and 96h after transfection (Figure 2, middle
panel). Conversely, Apollon downregulation failed to affect the
growth of MCF-7 cells at any time point considered (Figure 2,
lower panel).
Apollon knockdown induces apoptosis in breast cancer
cells
To investigate whether cell growth inhibition consequent on
Apollon knockdown was ascribable to the induction of apoptosis,
cells were stained with propidium iodide 72h after transfection,
and the presence of cells with an apoptotic nuclear morphology
was assessed by fluorescence microscopy. In all cell lines,
apoptosis was observed in a modest fraction of cells transfected
with the control siRNA (from 2.3 to 4.8% of the overall cell
population) and in mock control cells (from 1.7 to 3.8%).
Conversely, after the exposure of ZR75.1 cells to Apo2, the
percentage of apoptotic cells was about six-fold higher than that of
mock control (21.7 vs 3.8%) (Figure 3A). A significant, although
considerably less pronounced, increase in the percentage of
apoptotic cells was also observed in the MDA-MB-231 cells
transfected with Apo2 compared with that in mock control (9.3
vs 2.9%) (Figure 3A). Consistent with a negligible effect on cell
growth, in MCF-7 cells, Apollon knockdown did not induce any
increase in the apoptotic cell rate (Figure 3A).
Caspase catalytic activity was further assessed in all cell lines
72h after transfection. The results revealed that in ZR75.1 cells,
Apollon knockdown induced a 20-, 25- and 33-fold increase in
caspase-9, caspase-3 and caspase-8 catalytic activity, respectively,
compared with that in mock control (Figure 3B–D). A 10- and
17-fold increase in caspase-3 and caspase-8 catalytic activity,
respectively, was also observed in MDA-MB-231 cells after
exposure to Apo2 (Figure 3C and D), although no appreciable
effect on caspase-9 activity was recorded in this cell line
(Figure 3B). In MCF-7 cells, exposure to Apo2 induced a 17-fold
increase in caspase-9 catalytic activity compared with that in mock
control. In agreement with the lack of functional caspase-3 in this
cellular model (Janicke et al, 1998; Yang et al, 1998), no enzyme
activity was detectable under any of the treatment conditions
(Figure 3C). Moreover, no appreciable activation of caspase-8 was
observed in this cell line (Figure 3D).
The activation of caspase-9 in ZR75.1 and MCF-7 cells suggested
that the intrinsic (mitochondrial) pathway of apoptosis is activated
by Apollon knockdown only in breast cancer cells bearing wild-
type p53. To confirm this, we assessed by western blot the total
amount of p53 after Apollon silencing in the different cell lines
(Figure 4A). The wild-type p53 levels in ZR75.1 and MCF-7 cells
increased markedly after transfection with Apo2 (Figure 4A),
whereas the inherently high levels of mutant p53 protein in MDA-
MB-231 cells did not vary with the treatment (Figure 4A). The
upregulation of p53 seemed to reflect protein stabilisation rather
than enhanced gene transcription, as no increase in p53 mRNA
levels was detected by RT–PCR in Apollon downregulated cells
(Figure 4B).
To explore in more detail the molecular mechanisms of the
induction of apoptosis by Apollon knockdown, we examined the
expression of proteins involved in the mitochondrial pathway.
Transfection with Apo2 induced the accumulation of Bax and Bad
proteins and a remarkable release of the AIF from mitochondria
into the cytosol in cells with wild-type p53, but not in cells
expressing mutant p53 (Figure 4C). In addition, although to a
variable extent, an increase in the total Smac/DIABLO was
observed in all cell lines (Figure 4C). The cytochrome c release
from mitochondria was also determined by ELISA after subcellular
fractionation (Figure 4D). The results indicated that Apollon
knockdown caused an enhancement of the cytochrome c cytosolic
fraction in the two cell lines expressing wild-type p53. Specifically,
the release of cytochrome c was 12- and 9-fold higher in ZR75.1
and MCF-7 cells treated with Apo2, respectively, than in cells
transfected with the control siRNA (Figure 4D). By contrast, in
MDA-MB-231 cells bearing mutant p53, Apollon knockdown did
not cause any cytochrome c release (Figure 4D). Such findings
were corroborated by western blot data obtained on isolated
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Figure 2 Effects of Apollon downregulation on in vitro growth of breast
cancer cells. Survival curves of ZR75.1, MDA-MB-231 and MCF-7 cells
exposed to mock control (~) or transfected with ctr (’) and Apo2 (m)
siRNAs. Points represent the mean values±s.d. of at least three
independent experiments. *Po0.05, **Po0.01 and ***Po0.001 vs mock
control.
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smitochondrial and cytosolic fractions, which indicated a marked
decrease in the amount of cytochrome c remaining in mitochon-
dria in ZR75.1 and MCF-7 cells, but not in MDA-MB-231 cells
(Figure 4E).
Wild-type p53 and caspase-3 seem to be necessary for the
execution of apoptosis induced by Apollon knockdown
To determine to what extent wild-type p53 influences the
induction of apoptosis consequent on Apollon downregulation,
we knocked down p53 in ZR75.1 cells by RNAi. Pre-incubation of
cells with p53-specific siRNA resulted in a partial rescue of cell
growth inhibition (Figure 5) and a marked reduction of apoptosis
(Figure 3). These observations, which are consistent with the
modest level of apoptosis observed in Apo2-transfected MDA-MB-
231 cells, bearing mutant p53 (Figure 3), suggest that the wild-type
p53 protein is a major player in the induction of programmed cell
death by Apollon knockdown.
It is noteworthy that apoptosis induction resulting from Apollon
silencing was only reduced partially, but not abrogated completely
after p53 knockdown, suggesting that Apollon downregulation can
also interfere with caspase-3 activity in a p53-independent manner.
To address this hypothesis, we tested the effect of the simultaneous
knockdown of caspase-3 and Apollon in ZR75.1 cells. We found
that the siRNA-mediated inhibition of caspase-3 catalytic activity
resulted in the complete rescue of cell growth inhibition induced
by Apollon silencing (Figure 5), as well as in the total abrogation of
apoptosis although in the presence of activated caspase-9
(Figure 3). These findings are reminiscent of what we observed
in MCF-7 cells transfected with Apo2 (Figures 2 and 3), in which
induction of apoptosis was prevented by the absence of caspase-3
also in the presence of caspase-9 activation.
DISCUSSION
In this study, we evaluated the effects of RNAi-mediated Apollon
gene silencing in human breast cancer cell lines. Transfection with
a siRNA able to consistently induce an almost complete abrogation
of Apollon protein expression in all cell lines, variably influenced
cell growth as a function of TP53 gene status of the tumour model
and the availability of a functional caspase-3. Specifically, in the
wild-type-p53 ZR75.1 cells, Apollon silencing caused a marked
impairment of cell growth, which was paralleled by upregulation of
p53, activation of the mitochondrial apoptotic pathway including
Bax upregulation, release of cytochrome c and AIF from
mitochondria, and consequent enhancement of caspase-9 and
caspase-3 activity. The activation of caspase-8 was also observed.
Likewise, p53 upregulation and activation of the mitochondrial
pathway was also observed in the wild-type-p53 MCF-7 cell line.
However, as these cells lack caspase-3 (Janicke et al, 1998; Yang
et al, 1998), no cell growth impairment and no evidence of caspase-
8 activation or apoptosis induction was found in these cells.
Although to a lesser extent, compared with ZR75.1 cells, growth
retardation, as well as apoptosis induction as a consequence of
enhanced caspase-3 and caspase-8 activity were also observed in
ZR75.1 MDA-MB-231 MCF-7
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Figure 3 Effects of Apollon downregulation on the apoptotic rate of breast cancer cells. (A) The percentage of cells with an apoptotic nuclear
morphology as assessed by fluorescence microscopy in ZR75.1, MDA-MB-231 and MCF-7 cells 72h after transfection with siRNAs. Data represent the
mean values±s.d. of at least three independent experiments. *Po0.01 and **Po0.001 vs mock control. (B) Caspase-9, (C) caspase-3 and (D) caspase-8
catalytic activity as determined by hydrolysis of specific fluorogenic substrates 72h after transfection with siRNAs. Data are expressed as relative fluorescence
units and represent the mean values±s.d. of at least three independent experiments. *Po0.01 and **Po0.001 vs mock control. siRNA¼small interfering
RNA.
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smutant-p53 MDA-MB-231 cells. The latter finding, together with
the evidence that concomitant downregulation of p53 by RNAi
only partially rescued cell growth inhibition and reduced, but not
abrogated completely, apoptosis induced by Apollon knockdown
in ZR75.1 cells, led us to hypothesise that Apollon downregulation
can also directly or indirectly activate caspase-3 by a p53-
independent signal (Figure 6). Experimental support for this
hypothesis comes from experiments of simultaneous silencing of
caspase-3 and Apollon in ZR75.1 cells, which showed that the
abrogation of the enzyme’s catalytic activity resulted in a complete
rescue of cell growth inhibition and total abrogation of apoptosis
induced by Apollon silencing.
Our findings corroborate and extend earlier observations by
Ren et al (2005) indicating that inactivation of Bruce, the murine
homologue of Apollon, through deletion of the C-terminal UBC
domain, induced apoptosis in mouse embryonic fibroblasts
through upregulation and nuclear localisation of wild-type p53,
activation of the mitochondrial pathway of apoptosis and the
consequent activation of caspase-9 and caspase-3. The same
authors showed that the RNAi-mediated Apollon silencing in the
p53
þ/þ human lung cancer cell line H460, also induced a strong
apoptotic response as a consequence of p53-dependent activation
of the mitochondrial pathway. Moreover, simultaneous silencing of
Apollon and p53 in these cells induced only a partial rescue of cell
viability and a limited decrease in caspase-3 activation (Ren et al,
2005). Both our studies and Ren’s studies (Ren et al, 2005) point to
a central role of p53 as a downstream effector of Apollon/Bruce.
Although it is not known how Apollon knockdown causes p53
stabilisation, no interference with p53 gene transcription was
reported in either study. Considering that Apollon is itself an
E2/E3 ubiquitin ligase, it could act similarly to Mdm2, Pirh2 or
COP1, directly catalysing p53 ubiquitination and proteasome
degradation (Leng et al, 2003; Dornan et al, 2004).
The possibility that Apollon knockdown enhances caspase-3
catalytic activity in a direct way is supported by the observation of
Bartke et al (2004), who reported that Apollon interacts strongly
with caspase-3 and inhibits its activation in a cell-free extract of
293T adenovirus-transformed human embryo kidney cells. How-
ever, such findings were not confirmed by Qiu and Goldberg
(2005) in the same experimental model. An alternative possibility
is that increased caspase-3 activity could be the result of caspase-8
activation after Apollon knockdown. In this context, it has been
reported recently that apoptosis induction after transduction of
HT-1080 human fibrosarcoma cells with an oncolytic adenovirus,
expressing a short hairpin RNA against Apollon, was mediated by
the proteolytic activation of caspase-8 and caspase-3 (Chu et al,
2008).
In our study, we observed caspase-8 activation after Apollon
knockdown only in ZR75.1 and MDA-MB-231, but not in the
caspase-3-deficient MCF-7 cell line and in ZR75.1 cells after
siRNA-mediated caspase-3 silencing. Such evidence would suggest
a possible alternative interpretation of the results, in that the active
form of caspase-3 binds pro-caspase-8 and activates it (Sartorius
et al, 2001; Wajant, 2003), which in turn can activate caspase-3
(Figure 6). Somewhat surprisingly, the results we obtained in the
mutant-p53 MDA-MB-231 cells did not show any caspase-9
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Figure 4 Effects of Apollon downregulation on mitochondrial apoptotic pathway. Representative (A) western blot and (B) RT–PCR experiments
showing the expression of p53 protein and mRNA, respectively, in ZR75.1, MDA-MB-231 and MCF-7 cells 72h after transfection with ctr and Apo2 siRNAs.
(C) A representative western blot experiment showing the expression of proteins involved in the mitochondrial pathway, in ZR75.1, MDA-MB-231 and
MCF-7 cells 72h after transfection with ctr and Apo2 siRNAs. (D) Cytochrome c release as determined by ELISA in ZR75.1, MDA-MB-231 and MCF-7 cells
72h exposed to mock control or transfected with ctr and Apo2 siRNAs. Data are expressed as percentage values of cytosolic cytochrome c with respect to
the total amount of cytosolic and mitochondrial cytochrome c, and represent the mean values±s.d. of at least three independent experiments. *Po0.01
and **Po0.001 vs mock control. (E) A representative western blot experiment showing the abundance of cytochrome c in mitochondria and cytosolic
fractions in ZR75.1, MDA-MB-231 and MCF-7 cells 72h after transfection with ctr and Apo2 siRNAs. b-Actin and COX IV were used to confirm equal
protein loading and to show the relative purity of the cytosolic or mitochondrial fractions. AIF¼apoptosis inducing factor; siRNA¼small interfering RNA.
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sactivation after Apollon knockdown. In fact, earlier observations
obtained by Qiu and Goldberg (2005) in cell-free systems indicated
that immunopurified Apollon binds in vitro to pro-caspase-9 and
caspase-9 (although in a different study, only a weak binding of
Apollon to caspase-9 was detected (Bartke et al, 2004)), and
inhibits the enzyme’s catalytic activity (Qiu and Goldberg, 2005).
In addition, in 293T cells ectopically expressing Apollon, it was
shown that the protein ubiquitinated and facilitated the degrada-
tion of caspase-9 (Hao et al, 2004). However, as all this evidence
has been derived from cell-free systems or living cells forced to
express Apollon, it is difficult to compare it with the findings we
obtained in cells that were not manipulated to increase their
Apollon abundance. It is worthy to note that no published data
dealing with the interference of Apollon/Bruce with caspases on
cells expressing mutant p53 are currently available.
Overall, our results indicate that the Apollon gene silencing
causes growth impairment in breast cancer cells carrying a
wild-type or mutant p53 gene, mainly as a consequence of apoptosis
induction, and identifies p53 stabilisation and caspase-3 activation
as major events that concur to determine the apoptotic response.
These data also suggest the opportunity to conduct a survey of the
tumour types that express Apollon, and to further proceed with the
validation of Apollon as a potential new therapeutic target for
malignancies, in which it is overexpressed. However, considering
that in our study, a total decline of breast cancer cell growth was not
observed despite an almost complete abrogation of the Apollon
expression, targeting Apollon alone could be insufficient for
the effective treatment of tumours overexpressing it. As earlier
evidence points to the possibility of improving the activity of
specific anticancer drugs through Apollon knockdown (Chen et al,
1999; Chu et al, 2008), such a chemosensitising effect could be
exploited for the design of more effective therapies with Apollon
inhibitors combined with anticancer drugs to be used in the clinic,
after a preclinical validation of the most appropriate ways of
combining the different agents in chemoresistant tumour models.
However, as the presence of wild-type p53 and ‘normal’ caspase-3
expression seem to be the major determinants of the anti-
proliferative effects consequent to Apollon downregulation, the
possible induction of toxicity in normal tissues should be verified
carefully in animal models.
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